<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053231</url>
  </required_header>
  <id_info>
    <org_study_id>HERCOLES-2</org_study_id>
    <nct_id>NCT04053231</nct_id>
  </id_info>
  <brief_title>Hepatocarcinoma Recurrence on the Liver Study - Part2</brief_title>
  <acronym>HERCOLES2</acronym>
  <official_title>Hepatocarcinoma Recurrence on the Liver Study - Part2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale for the trial. To evaluate the impact of surgery on hepatocarcinoma recurrence.
      Thus, to evaluate the impact of different clinical, radiological, histopathological variables
      on recurrence after surgical treatment. The nature of this study will allow to observe, over
      time, the distribution of the considered collection variables, allowing a strictly
      observational monitoring of possible associations able to suggest models or interpretations,
      which can then be the basis for the construction of prospective and randomized studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is 1 of the 5 most common malignancies worldwide and the third
      most common cause of cancer related mortality of 500,000 deaths globally every year. Although
      more common in East Asia, the incidence of HCC is increasing in the Western world. Hepatic
      resection is the first-line therapeutic option and it is accepted as a safe treatment with a
      proven impact on prognosis, with a low operative mortality as the result of advances in
      surgical techniques and perioperative management. Nevertheless, surgical resection is
      applicable in only about 20% to 30% of patients with HCC, since most have poor hepatic
      reserve function caused by underlying chronic liver disease and multifocal hepatic
      distributions of HCC.

      Although hepatic resection is one of the curative treatments for hepatocellular carcinoma,
      the recurrence rate of HCC even after curative resection is quite high, estimated to be
      approximately 50 % during the first 3 years and more than 70 % during the first 5 years after
      curative resection, and so the postoperative long term results remain unsatisfactory. In this
      scenario the role of liver transplantation has been, in the last years, predominant, due to
      the ability of transplant to reduce disease recurrence, because of the treatment of liver
      cirrhosis associate to HCC which represent the most important driver to recurrence. Otherwise
      the scarcity of organ source has been a boost to the spread of liver resection, not only
      confined in the boundary taken into account in the BCLC algorithm (guidelines endorsed by
      EASL and AASLD), but even in patients considered not suitable for curative treatment as well
      as liver resection.

      Although surgical treatment has been adopted in the last years in more patients outside the
      Guidelines with satisfactory results in term of mortality, morbidity and Short term
      oncological outcomes, the limits of this approach remain the long term disease free survival.

      Risk factor for recurrence has been yet identified in the last years as hcc dimension,
      grading, microvascular invasion and satellitosis. The evidence that these two prognostic
      factors could negatively impact on the long term prognosis enhancing the risk of recurrence,
      has led many Author to propose anatomical resection (segmental resection) as the ideal
      surgical treatment to reduce these risks in HCC patients. Otherwise literature results are in
      conflict regarding the real benefit of this approach. In fact in many patients with HCC and
      underlying cirrhosis the anatomical approach is not feasible due to the risk of postoperative
      liver failure. So a parenchyma-sparing technique has been developed and compared to
      anatomical resection in term of oncological outcomes. Even if radiological and clinical
      pictures seems to predict the prognosis of resected HCC, the pathophysiology behind the
      recurrence is still unclear.Currently, data suggests two type of recurrence presentation:
      intrahepatic metastasization (IM) and multicentric occurrence (MO) of de novo HCC based on
      the precancerous status of the remnant diseased liver. Several effort has been done to
      preoperatively identified the 2 pattern of recurrences. Genetical studied has been performed,
      especially in eastern countries to better clarify and understand the impact of the 2
      phenomena. In the japanese guidelines are described histo-pathological hallmarks able, in
      retrospect, to define the type of recurrence, metastases or de novo tumor. Moreover, several
      recent studies including a metanalysis, seems to show that de novo recurrence could have a
      better prognosis when approached surgically, with a significant improvement in overall and
      disease-free survival rates. The model of HCC recurrence is not yet well clarified as well as
      the best treatment of hcc recurrence. On these data is based the proposal to create an
      Italian study project on surgical treatment and surgical outcomes of hepatocellular carcinoma
      in term of disease free survival. The idea growth up from the finding that, although the
      curative intent of surgical approach, results are not so satisfactory and it seems to not
      ameliorate the long term patient's prognosis and long term disease-free outcome without the
      need for therapies, conditioning the real everyday life of patient. In Italy is not yet
      present a study group that draw together the experience of surgical centers with low,medium
      or high volume of surgical procedures on HCC, with the intent to offer radical cure through
      surgery as the first choice treatment. The intent is to collect Big Data through a common
      database, with high power of analysis and high scientific impact, to better understand the
      mechanism which regulate HCC recurrence and to identify the best clinical treatment option
      for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">May 2034</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Disease-free-Survival</measure>
    <time_frame>15 years of follow-up</time_frame>
    <description>Disease Free Survival: the time between surgery and event of recurrence or death measured in months. If no event, patients will be censored at the last available follow-up date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>15 years of follow-up</time_frame>
    <description>The time from surgery to death measured in months. If no event, patients will be censored at the last available follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Localization of the recurrence</measure>
    <time_frame>15 years of follow-up</time_frame>
    <description>Presence of relapse disease on the surgical cut surface rather than at distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of redo-surgery</measure>
    <time_frame>15 years</time_frame>
    <description>Number of patients who experienced a recurrence after first surgery and has been submitted to a redo-surgery procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Surgery</condition>
  <condition>Recurrence Tumor</condition>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liver resection</intervention_name>
    <description>all type of liver surgical procedures</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients treated by surgery for HCC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No age limit.

          -  Hepatocarcinoma diagnosis confirmed at histological specimen

          -  Every single patients with first HCC diagnosis or with a recurrence/persistence
             disease evaluated and treated with surgery at the participating center.

          -  the assessment for patient enrollment must have been performed starting from
             02/02/2019.

        Exclusion Criteria:

          -  Surgery as a downstaging therapy for transplant

          -  Patients treated with surgery in case of not-curative intent (palliation, best
             supportive care, etc).

          -  Histopathological specimen of combined liver primary neoplasms (e.g.
             &quot;hepatocholangiocarcinoma'').

          -  Patients with other tumors in the previous past.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio Romano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan-Bicocca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simone Famularo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan Bicocca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Famularo, MD</last_name>
    <phone>+393296533353</phone>
    <email>simone.famularo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Ciulli, MD</last_name>
    <phone>+393896460025</phone>
    <email>c.ciulli@campus.unimib.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chirurgia Rubino - Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Riccardo Memeo, MD</last_name>
      <email>info@drmemeoriccardo.com</email>
    </contact>
    <investigator>
      <last_name>Riccardo Memeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore- AUSL</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Matteo Zanello, MD</last_name>
      <email>m.zanello@ausl.bologna.it</email>
    </contact>
    <investigator>
      <last_name>Elio Jovine, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Zanello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia Generale Bolzano</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Frena, MD</last_name>
      <email>antonio.frena@sabes.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Frena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza - Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Zimmitti, MD</last_name>
      <email>giuseppe.zimmitti@poliambulanza.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Zimmitti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gianluca Baiocchi, MD, PhD</last_name>
      <email>gianluca.baiocchi@unibs.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Baiocchi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Molfino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia Generale Ospedale Pierantoni - Morgagni</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuliano La Barba, MD</last_name>
      <email>labarba.giuliano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giorgio Ercolani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzoni - ASST Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Chiarelli, MD</last_name>
      <email>mee.chiarelli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marco Chiarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST-Mantova</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michela De Angelis, MD</last_name>
      <email>michela.deangelis@asst-mantova.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michela De Angelis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asst-Fbf-Sacco Polo Universitario H. Sacco Chirurgia 2</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Crespi, MD</last_name>
      <email>crespi.michele@asst-fbf-sacco.it</email>
    </contact>
    <investigator>
      <last_name>Michele Crespi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Osp. San Raffaele, Divisione Chirurgia Generale Epatobiliare</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federica Cipriani, MD</last_name>
      <email>cipriani.federica@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Luca Aldrighetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Adelmo Antonucci, MD</last_name>
      <email>adelmo.antonucci@policlinicodimonza.it</email>
    </contact>
    <investigator>
      <last_name>Adelmo Antonucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOS Chirurgia Oncologica ad inidirzzo epato-bilio-pancreatico</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Raffaele Dalla Valle, MD</last_name>
      <email>raffaele.dallavalle@unipr.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Iaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffaele Dalla Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcello Maestri, MD, PhD</last_name>
      <email>marcello.maestri@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Marcello Maestri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tommaso Dominioni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli, IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Ardito, Prof</last_name>
      <email>francesco.ardito@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Felice Giuliante, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Ardito, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Valerio De Peppo, MD</last_name>
      <email>valerio.depeppo2794@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gianluca Grazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerio De Peppo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Matteo Donadon, MD, PhD</last_name>
      <email>matteo.donadon@hunimed.eu</email>
    </contact>
    <investigator>
      <last_name>Guido Torzilli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Donadon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Savona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cecilia Ferrari, MD</last_name>
      <email>cecia8981@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guido Griseri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Ferrari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia 4 Ospedale Ca'Foncello</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Enrico Lodo, MD</last_name>
      <email>enrico.lodo@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo Zanus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Lodo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia Epatobiliare Università degli studi di Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrea Ruzzenente, MD</last_name>
      <email>ruzzenentea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Ruzzenente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Conci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.hercolesgroup.eu</url>
    <description>All the informations and protocol are available at the website</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>Fabrizio Romano</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>hcc</keyword>
  <keyword>hepatocarcinoma</keyword>
  <keyword>surgery</keyword>
  <keyword>redo surgery</keyword>
  <keyword>recurrence</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

